Quinupristin/dalfopristin
- PMID: 12186626
- DOI: 10.1517/14656566.3.9.1341
Quinupristin/dalfopristin
Abstract
Gram-positive pathogens are associated with both community- and hospital-acquired infections. These infections may be life-threatening in hospitalised patients, especially in those with significant underlying acute or chronic diseases. Prompt and appropriate antimicrobial therapy is essential for avoiding morbidity and mortality. The concept of appropriate therapy is being redefined by increasing antimicrobial resistance, especially amongst Gram-positive pathogens. This has been most dramatic with penicillin-resistant Streptococcus pneumoniae in the community, including cross-resistance to other classes of antimicrobial agents. In the US, the incidence of methicillin-resistant Staphylococcus aureus (MRSA) with community isolates is significant. For hospital-acquired Gram-positive pathogens, MRSA, vancomycin-resistant Enterococcus species and vancomycin-intermediate resistant and -resistant S. aureus are a great concern, particularly as the frequency of recovery of these pathogens from infected patients increases. The net result of these various resistance issues is a reduction in the number of appropriate antimicrobial agents for treating infected patients. Quinupristin/dalfopristin is a parental streptogramin with a spectrum of activity that includes Gram-positive pathogens, including those resistant to other classes of antimicrobial compounds. In this review, data summarising the frequency of recovered Gram-positive pathogens from various infectious diseases, the escalating prevalence of resistance amongst Gram-positive pathogens and the factors making quinupristin/dalfopristin a suitable agent for treating patients infected with Gram-positive organisms will be discussed.
Similar articles
-
Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.J Antimicrob Chemother. 1997 May;39 Suppl A:139-43. doi: 10.1093/jac/39.suppl_1.139. J Antimicrob Chemother. 1997. PMID: 9511078 Review.
-
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008. Drugs. 1999. PMID: 10651391 Review.
-
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.Diagn Microbiol Infect Dis. 1998 Jul;31(3):437-51. doi: 10.1016/s0732-8893(98)80002-3. Diagn Microbiol Infect Dis. 1998. PMID: 9635235
-
In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.J Antimicrob Chemother. 1997 May;39 Suppl A:15-21. doi: 10.1093/jac/39.suppl_1.15. J Antimicrob Chemother. 1997. PMID: 9511057 Review.
-
Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.Cancer Treat Rev. 2003 Oct;29(5):431-40. doi: 10.1016/s0305-7372(03)00069-0. Cancer Treat Rev. 2003. PMID: 12972361 Review.
Cited by
-
Advances in Diagnostic Approaches and Therapeutic Management in Bovine Mastitis.Vet Sci. 2023 Jul 8;10(7):449. doi: 10.3390/vetsci10070449. Vet Sci. 2023. PMID: 37505854 Free PMC article. Review.
-
Staphylococcal skin infections in children: rational drug therapy recommendations.Paediatr Drugs. 2005;7(2):77-102. doi: 10.2165/00148581-200507020-00002. Paediatr Drugs. 2005. PMID: 15871629 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources